re information about
EpiVax, please visit
www.epivax.com.
About Tregitope
Tregitope is a set of peptides that induce the body's own natural
regulatory T cells. When administered in conjunction with other antigens or
protein immunogens, the response to these immunogens is diminished and altered
if the antigen/immunogens are co-administered with Epi- 13. Preliminary in
vitro and in vivo studies indicate that the modification of the immune
response is due to the induction of natural T reg cells. Read the original
article online at http://www.pubmedcentral.nih.gov/.
About National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) conducts
and supports basic and applied research to better understand, treat, and
ultimately prevent infectious, immunologic, and allergic diseases. For more
than 50 years, NIAID research has led to new therapies, vaccines, diagnostic
tests, and other technologies that have improved the health of millions of
people in the United States and around the world.
'/>"/>SOURCE EpiVax, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
EpiVax receives JDRF program funding to develop diabetes drug using natural regulatory T-cells2.
Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award3.
ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications4.
Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program5.
Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections6.
Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation7.
Jon M. Huntsman Receives American Cancer Society Medal of Honor8.
Keryx Biopharmaceuticals Receives Nasdaq Notification9.
Kaiser Permanente Receives the Most Stars in California Office of Patient Advocates Annual Quality Report Card10.
Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q11.
Naviscan Receives 510(k) Clearance for Stereo Navigator(TM) - the First Commercially Available Breast PET-Guided Biopsy Feature